Galectin Therapeutics, Inc. (GALT)
3.73
+0.02
(+0.54%)
USD |
NASDAQ |
Oct 16, 12:23
Galectin Therapeutics SG&A Expense (TTM) : 6.712M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.712M |
| March 31, 2026 | 6.229M |
| December 31, 2025 | 5.795M |
| September 30, 2025 | 5.682M |
| June 30, 2025 | 5.566M |
| March 31, 2025 | 5.68M |
| December 31, 2024 | 5.862M |
| September 30, 2024 | 5.876M |
| June 30, 2024 | 5.839M |
| March 31, 2024 | 5.993M |
| December 31, 2023 | 5.942M |
| September 30, 2023 | 6.235M |
| June 30, 2023 | 6.325M |
| March 31, 2023 | 6.281M |
| December 31, 2022 | 6.615M |
| September 30, 2022 | 6.558M |
| June 30, 2022 | 6.665M |
| March 31, 2022 | 6.82M |
| December 31, 2021 | 6.361M |
| September 30, 2021 | 6.253M |
| June 30, 2021 | 5.768M |
| March 31, 2021 | 5.446M |
| December 31, 2020 | 5.468M |
| September 30, 2020 | 5.399M |
| June 30, 2020 | 5.613M |
| Date | Value |
|---|---|
| March 31, 2020 | 5.69M |
| December 31, 2019 | 5.971M |
| September 30, 2019 | 6.372M |
| June 30, 2019 | 6.187M |
| March 31, 2019 | 6.972M |
| December 31, 2018 | 7.131M |
| September 30, 2018 | 6.709M |
| June 30, 2018 | 6.445M |
| March 31, 2018 | 5.232M |
| December 31, 2017 | 4.526M |
| September 30, 2017 | 4.321M |
| June 30, 2017 | 4.658M |
| March 31, 2017 | 4.893M |
| December 31, 2016 | 6.156M |
| September 30, 2016 | 6.759M |
| June 30, 2016 | 6.946M |
| March 31, 2016 | 7.698M |
| December 31, 2015 | 6.965M |
| September 30, 2015 | 6.85M |
| June 30, 2015 | 6.913M |
| March 31, 2015 | 6.637M |
| December 31, 2014 | 7.005M |
| September 30, 2014 | 6.76M |
| June 30, 2014 | 7.615M |
| March 31, 2014 | 7.032M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Mirum Pharmaceuticals, Inc. | 313.84M |
| ACADIA Pharmaceuticals, Inc. | 620.29M |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Anika Therapeutics, Inc. | 52.67M |
| Savara, Inc. | 56.71M |